Sirolimus interacts with pathways essential for podocyte integrity. - Wikidata - wikimedia - TriplyDB

Sirolimus interacts with pathways essential for podocyte integrity.

Sirolimus interacts with pathways essential for podocyte integrity.

http://www.wikidata.org/entity/Q45151652

about

De novo glomerular diseases after renal transplantation Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.The pros and the cons of mTOR inhibitors in kidney transplantation.Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice Rapamycin Regulates Bleomycin-Induced Lung Damage in SP-C-Deficient Mice Cellular effects of everolimus and sirolimus on podocytes.miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Proteinuria after kidney transplantation.Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults.mTOR inhibitors in pediatric kidney transplantation.Safety of mTOR inhibitors in adult solid organ transplantation.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.GSK3β inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility.Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling.Role of Ragulator in the Regulation of Mechanistic Target of Rapamycin Signaling in Podocytes and Glomerular Function.Conversion to sirolimus in pediatric renal transplant patients: a single-center experience.The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes.Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma.mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside.De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.The podocyte as a direct target of immunosuppressive agents

P2860

Q27005877-B495173C-9973-4142-8649-8295626230E0 Q28484885-4943F790-76C4-4E61-81F8-A1C849F4DBFF Q31108592-8F1DF39A-ED96-4470-8EB6-C56172D899E5 Q33412367-25350DC2-8B77-4F17-992F-EFA19D08992D Q33974535-FD8A1868-F5CD-4266-8C3F-5DEF3C488952 Q35029260-EBA3733C-555E-4EAD-A7E3-13F37B507061 Q35048950-81E6E18C-6EBD-4DC8-945A-1033DB1C685B Q35108868-FF07B141-6DC5-47D9-AFC5-8D4F308F4E7B Q36183858-F58F1152-8F65-4009-AE3D-24067D80C90F Q37760379-987780F9-F8A5-4C91-A1AC-164193B0A05B Q38012182-D74BE75F-CD22-4B01-BD25-4CA203F80B00 Q38085054-ED2A6DBD-7BC9-4525-B565-51656AF5CB01 Q38112331-508FFBA6-9F2F-464F-97A5-7DA5339E4A06 Q38669190-08013B41-0270-483F-B209-7710131C233A Q38914374-BEF96169-608B-4F99-8538-DA9784F73ABA Q39608726-186D2A5F-E96E-4861-96D0-C7FD56F851F9 Q42068754-88F19555-F1B7-44A3-B70C-9A72D745619E Q42491145-5233A57B-5A09-45C8-A254-1DDD68995EBC Q43808149-BBA3C9AE-1227-4AA5-8892-935B7BA747DC Q44658058-13F550FD-8F9B-49A1-8956-44364E708DA4 Q46182457-0278A3F3-2549-4E02-9734-055292616852 Q46764150-96ED1D25-C62B-46D7-9A1B-167D359D10B1 Q47172094-97891735-F39F-4818-A8B4-108A44A8EB66 Q51067478-0A510DDD-2899-4042-991F-3846D82579AF Q51547435-455C20D4-BFF3-408E-86DB-58184FD65D20 Q53425824-D7F7B1FD-C8F8-4738-8660-3DDD0A40ED52 Q54392480-5D038242-1387-4498-9C14-559F56D0C55B Q58177753-8351B53E-4BAC-44EB-9AEB-B071C8CE4CE1

P2860

Sirolimus interacts with pathways essential for podocyte integrity.

http://www.wikidata.org/entity/Q45151652

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Sirolimus interacts with pathways essential for podocyte integrity.

@en

Sirolimus interacts with pathways essential for podocyte integrity.

@nl

type

label

Sirolimus interacts with pathways essential for podocyte integrity.

@en

Sirolimus interacts with pathways essential for podocyte integrity.

@nl

prefLabel

Sirolimus interacts with pathways essential for podocyte integrity.

@en

Sirolimus interacts with pathways essential for podocyte integrity.

@nl

P1433

Q45151652-2824115D-4621-4793-82A9-A2650F477CBF

P1476

Q45151652-FC6BA167-B041-43EE-AEA6-E2191B9DE9A9

P2093

Q45151652-13ECC14F-A331-469C-B0C2-89863A34EC26

Q45151652-2AE82DB6-5F98-431A-A0A1-E560A7F23287

Q45151652-36B19F5D-C556-4F7C-934C-DEFF6CCF00DE

Q45151652-3EA48064-E094-4BDE-9FB4-E130FA491534

Q45151652-4D25789F-930D-46E2-AA84-5B9F826144C7

Q45151652-84020AC2-0AA6-4BEC-8FBE-3FE39491437E

Q45151652-A743393C-FEB8-44ED-9ADD-5C2650E0120F

Q45151652-F4DBABCE-5747-4224-8633-94BAB49D7CA9

P2860

Q45151652-10534953-8204-4BC7-8DCE-0A572D9734C6

Q45151652-22A5F6C5-368C-426C-BB81-B26370D651AA

Q45151652-277D22CF-0604-4392-B544-B24282D2053C

Q45151652-3016D5D9-1A22-43F7-BD8C-DD2820DF2E6A

Q45151652-330EA3F6-7773-4F9F-BEEF-F850591670C3

Q45151652-529B7CD5-3381-44DF-A2B1-C13EC286F320

Q45151652-57AEF94E-7120-4361-806F-AC92D6DDABC7

Q45151652-72994029-5866-41C8-9AD9-FFB9826DB566

Q45151652-75D447FF-5DD1-4131-A707-C7C7A549CA1E

Q45151652-7E91D675-CC97-49BE-8343-DC1369F0EB78

P304

Q45151652-ECE83AE8-DE27-4232-B55A-B788BC6CA4F8

P31

Q45151652-42DDFC8C-8012-4C6D-86BB-B721128AABAD

P356

Q45151652-4C567CBF-E2C1-4E39-A426-872CA36F6D03

P407

Q45151652-937D0F1F-2757-40F4-95D4-73758C4473F3

P433

Q45151652-9EC6753A-2F4C-457A-BA3E-FB9CE2415415

P478

Q45151652-70877610-C530-4547-844F-88E93DE86650

P50

Q45151652-048587BA-D18B-4396-8776-BC5B0946A24B

P577

Q45151652-B9A1E685-F621-49F7-992C-C268B4EA0810

P5875

Q45151652-7A7224CC-7B08-47E2-A35E-D09337C38121

P698

Q45151652-B68D10F1-3F07-486C-9D0C-E40FE191DB2A

P356

P1433

Nephrology Dialysis Transplantation

P1476

Sirolimus interacts with pathways essential for podocyte integrity.

@en

P2093

Chantal Mandet

http://www.w3.org/2001/XMLSchema#string

Christophe Legendre

http://www.w3.org/2001/XMLSchema#string

Emmanuel Letavernier

http://www.w3.org/2001/XMLSchema#string

Jean-philippe Haymann

http://www.w3.org/2001/XMLSchema#string

Joelle Perez

http://www.w3.org/2001/XMLSchema#string

Laurent Baud

http://www.w3.org/2001/XMLSchema#string

Marie-France Belair

http://www.w3.org/2001/XMLSchema#string

Sophie Vandermeersch

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling

The complex life of WT1

Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.

The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome.

Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP.

VEGF-C promotes survival in podocytes.

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.

P304

630-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFN574

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Bruneval

P577

2008-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23388688

http://www.w3.org/2001/XMLSchema#string

P698

18927120

http://www.w3.org/2001/XMLSchema#string